Hopp til innhold
NHI.no
Annonse

Polymyalgia revmatika: Årsaker

Innhold i artikkelen

Begge tilstander er trolig uttrykk for en betennelse i veggen på pulsårer (arteritt). Årsaken til at denne betennelsen oppstår, er ukjent. Man tror det er både ytre faktorer og arvelige faktorer som medvirker. En av teoriene er at tilstanden kan være utløst av en infeksjon, men dette er ikke etablert som et faktum. 

Annonse

Forekomsten av PMR og AT er høyere i Skandinavia enn i andre deler av verden. I Minnesota i USA er det også høy forekomst, noe en setter i forbindelse med høy innvandring av skandinaver langt tilbake i tid til denne delen av USA.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Polymyalgia rheumatica . Referanselisten for dette dokumentet vises nedenfor

  1. Tengesdal S, Diamantopoulos AP, Brekke LK, et al. Polymyalgia rheumatica. Nasjonal veileder i revmatologi. Sist oppdatert 21.01.2025. metodebok.no
  2. Buttgereit F, Dejaco C, Matteson EL, et al.. polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 2016;315:2442–58. PMID: 27299619 PubMed
  3. González-Gay MA, Matteson EL, Castañeda S. Polymyalgia rheumatica. Lancet. 2017 Oct 7;390(10103):1700-1712. Epub 2017 Jul 31. PMID: 28774422. PubMed
  4. Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014 Jul 3;371(1):50-7. PMID: 24988557. PubMed
  5. Rosenberg H, Halman S, Yadav K. Polymyalgia rheumatica. CMAJ. 2021 Nov 22;193(46):E1770. PMID: 34810164 PubMed
  6. Ezeonyeji AN, Borg FA, Dasgupta B. Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin Rheumatol. 2011;30(2):259–262.
  7. Gran JT, Myklebust G. Incidence and clinical characteristics of peripheral arthritis in polymyalgia rheumatica and temporal arteritis. Rheumatology 2000; 39: 283-7. Rheumatology
  8. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 2010; 49: 186-90. Rheumatology
  9. Kreiner F, Langberg H, Galbo H. Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum. 2010;62(12):3768–3775.
  10. González-Gay MA, Pina T. Giant cell arteritis and polymyalgia rheumatica: an update. Curr Rheumatol Rep. 2015 Feb;17(2):6. PMID: 25618572 PubMed
  11. Gilden D, White T, Khmeleva N, et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology 2015. DOI: 10.1212/WNL.0000000000001409 DOI
  12. Liozon E, Parreau S, Filloux M, et al. Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: A study of 12 patients and a literature review. Autoimmunity Reviews 2021. pubmed.ncbi.nlm.nih.gov
  13. Dasgupta B, Cimmino MA, Maradit-Kremers H et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012; 65: 943-54. www.ncbi.nlm.nih.gov
  14. Macchioni P1, Boiardi L, Catanoso M, Pazzola G, Salvarani C. Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. Ann Rheum Dis 2014; 73: 1190-3. pmid:24297384 PubMed
  15. Ozen G, Inanc N, Unal AU, et al. Assessment of the New 2012 EULAR/ACR Clinical Classification Criteria for Polymyalgia Rheumatica: A Prospective Multicenter Study. J Rheumatol 2016. pmid:26834222 PubMed
  16. Mackie SL, Hensor EM, Haugeberg G, Bhakta B, Pease CT. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford). 2010;49(4):716–722.
  17. Breuer GS, Nesher G. What does imaging tell us about polymyalgia rheumatica? Rheumatology 2011; 51: 5-6. Rheumatology
  18. Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015; 74(10): 1799-807. Pmid: 26359488.
  19. Allen CS, Yeung JH, Vandermeer B, et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016 Oct 5;10:CD001347. pmid: 27706804 PubMed
  20. Rosen HN, Saag KG. Prevention and treatment of glucocorticoid-induced osteoporosis. UpToDate. Sist revidert juni 2015. www.uptodate.com
  21. Marsman DE, den Broeder N, van den Hoogen FHJ, et al. Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial. Lancet Rheumatol 2021. doi:10.1016/S2665-9913(21)00245-9 DOI
  22. Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy A Randomized Clinical Trial. JAMA 2022; 328: 1053-62. pmid:36125471 PubMed
  23. Spiera RF, Unizony S, Warrington KJ, et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med 2023 Oct 5; 389:1263. PMID: 37792612 PubMed
  24. Kermani TA, Warrington KJ, Cuthbertson D, et al. Disease relapses among patients with giant cell arteritis: A prospective, longitudinal cohort study. J Rheumatol 2015; 42:1213. doi: 10.3899/jrheum.141347 DOI
  25. Dejaco C, Duftner C, Cimmino MA, Dasgupta B, Salvarani C, Crowson CS, Maradit-Kremers H, Hutchings A, Matteson EL, Schirmer M; International Work Group for PMR and GCA. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis. 2011;70:447–453
  26. Wu J, Keeley A, Mallen C et al. Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. CMAJ 2019; 191: E680-8. pmid:31235489 PubMed
  27. Faurschou M, Ahlstrom MG, Lindhardsen J, et al. Risk of Diabetes mellitus among patients diagnosed with giant cell arteritis or granulomatosis with polyangiitis: Comparison with the general population. J Rheumatol. 2016 . PMID:27744394 PubMed
  28. Narváez J, Estrada P, López-Vives L, et al.. Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica. Semin Arthritis Rheum. 2015 Dec;45(3):328-33. doi: 10.1016/j.semarthrit.2015.06.009. Epub 2015 Jun 19. PMID: 26186807 PubMed
  29. De Miguel E, Macchioni P, Conticini E, Campochiaro C, Karalilova R, Monti S, Ponte C, Klinowski G, Monjo-Henry I, Falsetti P, Batalov Z, Tomelleri A, Hocevar A. Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica. Rheumatology (Oxford). 2024 Jan 4;63(1):158-164. doi: 10.1093/rheumatology/kead189. PMID: 37129541 PubMed
  30. Hancock AT, Mallen CD, Muller S, et al. Risk of vascular events in patients with polymyalgia rheumatica. CMAJ. 2014 Jul 28.
  31. Pujades-Rodriguez M, Duyx B, Thomas SL, et al. Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases. Heart 2016. doi:10.1136/heartjnl-2015-308514 DOI
  32. Dasgupta B, Borg FA, Hassan N, et al.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010;49(1):186–190.
Annonse
Annonse